|
WO2020081986A1
|
|
Tlr9 modulators for treating cancer
|
|
AU2017325981A1
|
|
Immune modulation with TLR9 agonists for cancer treatment
|
|
WO2017205384A1
|
|
Compositions and methods for inhibiting target rna expression
|
|
WO2017136399A1
|
|
POTENTIATION OF mmRNA THERAPEUTICS
|
|
EP3371328A2
|
|
Compositions for inhibiting nlrp3 gene expression and uses thereof
|
|
WO2017007886A2
|
|
Compositions for inhibiting dux4 gene expression and uses thereof
|
|
US2016251652A1
|
|
Compositions for inhibiting checkpoint gene expression and uses thereof
|
|
US2016237437A1
|
|
Toll-like receptor 9 antagonist and methods of use thereof
|
|
CN106999574A
|
|
Use TLR9 activators and treatment of the checkpoint inhibitor to cancer
|
|
AU2014203624A1
|
|
Novel synthetic agonists of TLR9
|
|
CA2896537A1
|
|
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
EP2640420A2
|
|
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
JP2012051921A
|
|
Immunostimulatory property of oligonucleotide-based compound comprising modified immunostimulatory dinucleotide
|
|
EP2588143A2
|
|
Novel agonists of toll-like receptor 3 and methods of their use
|
|
CN104673795A
|
|
Compositions for inhibiting gene expression and uses thereof
|
|
CN102612561A
|
|
Potentiation of autoimmune and inflammatory disease treatments by immune regulatory oligonucleotide (iro) antagonists of tlr7 and tlr9
|
|
EP2396409A2
|
|
Synthetic rna-based agonists of tlr7
|
|
MX2011008067A
|
|
Synthetic agonists of tlr 9.
|
|
US2010111935A1
|
|
Modulation of Toll-Like Receptor 2 Expression By Antisense Oligonucleotides
|
|
AU2009313604A1
|
|
Modulation of toll-like receptor 4 expression by antisense oligonucleotides
|
